RhoA, a possible target for treatment of airway hyperresponsiveness in bronchial asthma

Journal of Pharmacological Sciences

Volumn 114, Issue 3, 2010, Pages 239-247

  Chiba, Yoshihiko ^a   Matsusue, Kimihiko ^b   Misawa, Miwa ^a  

^a HOSHI UNIVERSITY   (Japan)

^b FUKUOKA UNIVERSITY   (Japan)

Author keywords

Airway hyperresponsiveness; Allergic bronchial asthma; Bronchial smooth muscle; RhoA

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; CALCIUM ION; MICRORNA; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN;

ASTHMA; BINDING SITE; BRONCHUS HYPERREACTIVITY; DISEASE ACTIVITY; DRUG MECHANISM; ERECTILE DYSFUNCTION; GENE EXPRESSION REGULATION; GENE LOCATION; HUMAN; HYPERTENSION; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; RNA SEQUENCE; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTION; TRANSCRIPTION REGULATION;

EID: 78649424607     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.10R03CR     Document Type: Review

References (82)

1. Eder W, Ege MJ, von Mutius E. The asthma epidemic. N Engl J Med. 2006;355:2226-2235.
2. Martin JG, Duguet A, Eidelman DH. The contribution of airway smooth muscle to airway narrowing and airway hyperresponsiveness in disease. Eur Respir J. 2000;16:349-354.
3. Roberts JA, Raeburn D, Rodger IW, Thomson NC. Comparison of in vivo airway responsiveness and in vitro smooth muscle sensitivity to methacholine in man. Thorax. 1984;39:837-843.
4. Björck T, Gustafsson LE, Dahlén SE. Isolated bronchi from asthmatics are hyperresponsive to adenosine, which apparently acts indirectly by liberation of leukotrienes and histamine. Am Rev Respir Dis. 1992;145:1087-1091.
5. Ma X, Cheng Z, Kong H, Wang Y, Unruh H, Stephens NL, et al. Changes in biophysical and biochemical properties of single bronchial smooth muscle cells from asthmatic subjects. Am J Physiol Lung Cell Mol Physiol. 2002;283:L1181-L1189.
6. McParland BE, Tait RR, Paré PD, Seow CY. The role of airway smooth muscle during an attack of asthma simulated in vitro. Am J Respir Cell Mol Biol. 2005;33:500-504.
7. Gavett SH, Wills-Karp M. Elevated lung G protein levels and muscarinic receptor affinity in a mouse model of airway hyperreactivity. Am J Physiol. 1993;265:L493-L500.
8. Lee JY, Uchida Y, Sakamoto T, Hirata A, Hasegawa S, Hirata F. Alteration of G protein levels in antigen-challenged guinea pigs. J Pharmacol Exp Ther. 1994;271:1713-1720.
9. Misawa M, Chiba Y. Repeated antigenic challenge-induced airway hyperresponsiveness and airway inflammation in actively sensitized rats. Jpn J Pharmacol. 1993;61:41-50.
10. Chiba Y, Misawa M. Characteristics of muscarinic cholinoceptors in airways of antigen-induced airway hyperresponsive rats. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1995; 111:351-357.
11. 2+ availability involved in antigen-induced airway hyperresponsiveness in rats. Eur J Pharmacol. 1995;278:79-82.
12. Chiba Y, Goto K, Hirahara M, Sakai H, Misawa M. Glucocorticoids ameliorate antigen-induced bronchial smooth muscle hyperresponsiveness by inhibiting upregulation of RhoA in rats. J Pharmacol Sci. 2008;106:615-625.
13. 2+ sensitization in antigen-induced bronchial smooth muscle hyperresponsiveness in mice. Respir Res. 2005;6:Art. No. 4.
14. Chiba Y, Ueno A, Sakai H, Misawa M. Hyperresponsiveness of bronchial but not tracheal smooth muscle in a murine model of allergic bronchial asthma. Inflamm Res. 2004;53:636-642.
15. Gosens R, Schaafsma D, Nelemans SA, Halayko AJ. Rho-kinase as a drug target for the treatment of airway hyperresponsiveness in asthma. Mini Rev Med Chem. 2006;6:339-348.
16. Schaafsma D, Gosens R, Zaagsma J, Halayko AJ, Meurs H. Rho kinase inhibitors: a novel therapeutical intervention in asthma? Eur J Pharmacol. 2008;585:398-406.
17. Schaafsma D, Roscioni SS, Meurs H, Schmidt M. Monomeric G-proteins as signal transducers in airway physiology and pathophysiology. Cell Signal. 2008;20:1705-1714.
18. Kume H. RhoA/Rho-kinase as a therapeutic target in asthma. Curr Med Chem. 2008;15:2876-2885.
19. 2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev. 2003;83:1325-1358.
20. 2+ signaling and sensitivity. Proc Am Thorac Soc. 2008;5:23-31.
21. Sato K, Ozaki H, Karaki H. Changes in cytosolic calcium level in vascular smooth muscle strip measured simultaneously with contraction using fluorescent calcium indicator fura 2. J Pharmacol Exp Ther. 1988;246:294-300.
22. 2+ and contraction induced by various stimulants and relaxants in canine tracheal smooth muscle. Pflugers Arch. 1990;416: 351-359.
23. Satoh S, Kreutz R, Wilm C, Ganten D, Pfitzer G. Augmented agonist-induced Ca2+-sensitization of coronary artery contraction in genetically hypertensive rats. Evidence for altered signal transduction in the coronary smooth muscle cells. J Clin Invest. 1994;94:1397-1403.
24. 2+ sensitization of skinned muscle of guinea pig vas deferens. J Pharmacol Exp Ther. 1995; 274:555-561.
25. Bremerich DH, Warner DO, Lorenz RR, Shumway R, Jones KA. Role of protein kinase C in calcium sensitization during muscarinic stimulation in airway smooth muscle. Am J Physiol. 1997; 273:L775-L781.
26. 2+ sensitization of bronchial smooth muscle contraction in antigen-induced airway hyperresponsive rats. Br J Pharmacol. 1999;127:597-600.
27. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 1997;389: 990-994.
28. Nagumo H, Sasaki Y, Ono Y, Okamoto H, Seto M, Takuwa Y. Rho kinase inhibitor HA-1077 prevents Rho-mediated myosin phosphatase inhibition in smooth muscle cells. Am J Physiol Cell Physiol. 2000;278:C57-C65.
29. Chiba Y, Takeyama H, Sakai H, Misawa M. Effects of Y-27632 on acetylcholine-induced contraction of intact and permeabilized intrapulmonary bronchial smooth muscles in rats. Eur J Pharmacol. 2001;427:77-82.
30. Mukai Y, Shimokawa H, Matoba T, Kandabashi T, Satoh S, Hiroki J, et al. Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension. FASEB J. 2001;15:1062-1064.
31. Seko T, Ito M, Kureishi Y, Okamoto R, Moriki N, Onishi K, et al. Activation of RhoA and inhibition of myosin phosphatase as important components in hypertension in vascular smooth muscle. Circ Res. 2003;92:411-418.
32. Shimokawa H, Seto M, Katsumata N, Amano M, Kozai T, Yamawaki T, et al. Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm. Cardiovasc Res. 1999;43:1029-1039.
33. Kandabashi T, Shimokawa H, Miyata K, Kunihiro I, Kawano Y, Fukata Y, et al. Inhibition of myosin phosphatase by upregulated rho-kinase plays a key role for coronary artery spasm in a porcine model with interleukin-1beta. Circulation. 2000;101:1319-1323.
34. Hiroki J, Shimokawa H, Higashi M, Morikawa K, Kandabashi T, Kawamura N, et al. Inflammatory stimuli upregulate Rho-kinase in human coronary vascular smooth muscle cells. J Mol Cell Cardiol. 2004;37:537-546.
35. Sato M, Tani E, Fujikawa H, Kaibuchi K. Involvement of Rhokinase-mediated phosphorylation of myosin light chain in enhancement of cerebral vasospasm. Circ Res. 2000;87:195-200.
36. Chrissobolis S, Sobey CG. Evidence that Rho-kinase activity contributes to cerebral vascular tone in vivo and is enhanced during chronic hypertension: comparison with protein kinase C. Circ Res. 2001;88:774-779.
37. Niiro N, Nishimura J, Sakihara C, Nakano H, Kanaide H. Upregulation of rho A and rho-kinase mRNAs in the rat myometrium during pregnancy. Biochem Biophys Res Commun. 1997;230: 356-359.
38. 2+ sensitization of rabbit myometrium during pregnancy - role of Rnd3. J Physiol. 2003;552:403-413.
39. Chitaley K, Wingard CJ, Clinton Webb R, Branam H, Stopper VS, Lewis RW, et al. Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway. Nat Med. 2001;7:119-122.
40. Mills TM, Chitaley K, Wingard CJ, Lewis RW, Webb RC. Effect of Rho-kinase inhibition on vasoconstriction in the penile circulation. J Appl Physiol. 2001;91:1269-273.
41. Chitaley K, Bivalacqua TJ, Champion HC, Usta MF, Hellstrom WJ, Mills TM, et al. Adeno-associated viral gene transfer of dominant negative RhoA enhances erectile function in rats. Biochem Biophys Res Commun. 2002;298:427-432.
42. 2+ sensitization in erectile function. J Biol Chem. 2002;277:30614-30621.
43. Wingard CJ, Husain S, Williams J, James S. RhoA-Rho kinase mediates synergistic ET-1 and phenylephrine contraction of rat corpus cavernosum. Am J Physiol Regul Integr Comp Physiol. 2003;285:R1145-R1152.
44. Dai Y, Chitaley K, Webb RC, Lewis RW, Mills TM. Topical application of a Rho-kinase inhibitor in rats causes penile erection. Int J Impot Res. 2004;16:294-298.
45. 2+ sensitization of tracheal smooth muscle. Am J Physiol. 1998;275:L748-L755.
46. 2+ sensitization. Am J Respir Cell Mol Biol. 1999;20:1190-1200.
47. Yamagata S, Ichinose M, Sugiura H, Koarai A, Koike K, Shirato K. Effect of a calcium sensitization modulator, Y-27632, on isolated human bronchus and pulmonary artery. Pulm Pharmacol Ther. 2000;13:25-29.
48. Chiba Y, Uchida T, Sakai H, Oku T, Itoh S, Tsuji T, et al. Acetylcholine-induced translocation of RhoA in freshly isolated single smooth muscle cells of rat bronchi. J Pharmacol Sci. 2004; 95:479-482.
49. 2+ and myosin phosphorylation, but not calmodulin activity in sensitized airway smooth muscles. Am J Physiol. 1995;268:L739-L746.
50. 2+ sensitization of the bronchial smooth muscle contraction in antigen-induced airway hyperresponsive rats. Res Commun Mol Pathol Pharmacol. 1999;106:77-85.
51. Chiba Y, Sakai H, Wachi H, Sugitani H, Seyama Y, Misawa M. Upregulation of rhoA mRNA in bronchial smooth muscle of antigen-induced airway hyperresponsive rats. J Smooth Muscle Res. 2003;39:221-228.
52. Chiba Y, Nakazawa S, Todoroki M, Shinozaki K, Sakai H, Misawa M. Interleukin-13 augments bronchial smooth muscle contractility with an up-regulation of RhoA protein. Am J Respir Cell Mol Biol. 2009;40:159-167.
53. Chiba Y, Todoroki M, Nishida Y, Tanabe M, Misawa M. A novel STAT6 inhibitor AS1517499 ameliorates antigen-induced bronchial hypercontractility in mice. Am J Respir Cell Mol Biol. 2009;41:516-524.
54. Chiba Y, Tanabe M, Goto K, Sakai H, Misawa M. Down-regulation of miR-133a contributes to up-regulation of RhoA in bronchial smooth muscle cells. Am J Respir Crit Care Med. 2009; 180:713-719.
55. Seabra MC. Membrane association and targeting of prenylated Ras-like GTPases. Cell Signal. 1998;10:167-172.
56. Williams CL. The polybasic region of Ras and Rho family small GTPases: a regulator of protein interactions and membrane association and a site of nuclear localization signal sequences. Cell Signal. 2003;15:1071-1080.
57. Forget MA, Desrosiers RR, Gingras D, Béliveau R. Phosphorylation states of Cdc42 and RhoA regulate their interactions with Rho GDP dissociation inhibitor and their extraction from biological membranes. Biochem J. 2002;361:243-254.
58. Lang P, Gesbert F, Delespine-Carmagnat M, Stancou R, Pouchelet M, Bertoglio J. Protein kinase A phosphorylation of RhoA mediates the morphological and functional effects of cyclic AMP in cytotoxic lymphocytes. EMBO J. 1996;15:510-519.
59. Sawada N, Itoh H, Yamashita J, Doi K, Inoue M, Masatsugu K, et al. cGMP-dependent protein kinase phosphorylates and inactivates RhoA. Biochem Biophys Res Commun. 2001;280:798-805.
60. Delpuech O, Trabut JB, Carnot F, Feuillard J, Brechot C, Kremsdorf D. Identification, using cDNA macroarray analysis, of distinct gene expression profiles associated with pathological and virological features of hepatocellular carcinoma. Oncogene. 2002;21:2926-2937.
61. Li XR, Ji F, Ouyang J, Wu W, Qian LY, Yang KY. Overexpression of RhoA is associated with poor prognosis in hepatocellular carcinoma. Eur J Surg Oncol. 2006;32:1130-1134.
62. Wang D, Dou K, Xiang H, Song Z, Zhao Q, Chen Y, et al. Involvement of RhoA in progression of human hepatocellular carcinoma. J Gastroenterol Hepatol. 2007;22:1916-1920.
63. Yoshioka K, Nakamori S, Itoh K. Overexpression of small GTPbinding protein RhoA promotes invasion of tumor cells. Cancer Res. 1999;59:2004-2010.
64. Goto K, Chiba Y, Matsusue K, Hattori Y, Maitani Y, Sakai H, et al. The proximal STAT6 and NF-kappaB sites are responsible for IL-13-and TNF-alpha-induced RhoA transcriptions in human bronchial smooth muscle cells. Pharmacol Res. 2010;61:466-472.
65. Goto K, Chiba Y, Sakai H, Misawa M. Mechanism of inhibitory effect of prednisolone on RhoA upregulation in human bronchial smooth muscle cells. Biol Pharm Bull. 2010;33:710-713.
66. Chiba Y, Goto K, Matsusue K, Kimura S, Misawa M. Identification and characterization of rat RhoA gene promoter. J Pharmacol Sci. 2010;112:467-472.
67. Berry MA, Parker D, Neale N, Woodman L, Morgan A, Monk P, et al. Sputum and bronchial submucosal IL-13 expression in asthma and eosinophilic bronchitis. J Allergy Clin Immunol. 2004;114:1106-1109.
68. Saha SK, Berry MA, Parker D, Siddiqui S, Morgan A, May R, et al. Increased sputum and bronchial biopsy IL-13 expression in severe asthma. J Allergy Clin Immunol. 2008;121:685-691.
69. Goto K, Chiba Y, Misawa M. IL-13 induces translocation of NFkappaB in cultured human bronchial smooth muscle cells. Cytokine. 2009;46:96-99.
70. Sakai H, Otogoto S, Chiba Y, Abe K, Misawa M. TNF-alpha augments the expression of RhoA in the rat bronchus. J Smooth Muscle Res. 2004;40:25-34.
71. Sakai H, Otogoto S, Chiba Y, Abe K, Misawa M. Involvement of p42/44 MAPK and RhoA protein in augmentation of AChinduced bronchial smooth muscle contraction by TNF-alpha in rats. J Appl Physiol. 2004;97:2154-2159.
72. Goto K, Chiba Y, Sakai H, Misawa M. Tumor necrosis factoralpha (TNF-alpha) induces upregulation of RhoA via NF-kappaB activation in cultured human bronchial smooth muscle cells. J Pharmacol Sci. 2009;110:437-444.
73. de Lima FM, Bjordal JM, Albertini R, Santos FV, Aimbire F. Low-level laser therapy (LLLT) attenuates RhoA mRNA expression in the rat bronchi smooth muscle exposed to tumor necrosis factor-alpha. Lasers Med Sci. 2010;25:661-668.
74. Ambros V. The functions of animal microRNAs. Nature. 2004; 431:350-355.
75. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281-297.
76. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215-233.
77. Carè A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P, et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med. 2007;13:613-618.
78. Rehmsmeier M, Steffen P, Hochsmann M, Giegerich R. Fast and effective prediction of microRNA/target duplexes. RNA. 2004; 10:1507-1517.
79. Chiba Y, Misawa M. MicroRNAs and their therapeutic potential for human diseases: MiR-133a and bronchial smooth muscle hyperresponsiveness in asthma. J Pharmacol Sci. 2010;114:264-268.
80. Kong W, Yang H, He L, Zhao JJ, Coppola D, Dalton WS, Cheng JQ. MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol. 2008;28:6773-6784.
81. Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szász AM, Wang ZC, et al. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell. 2009;137:1032-1046.
82. Valastyan S, Chang A, Benaich N, Reinhardt F, Weinberg RA. Concurrent suppression of integrin alpha5, radixin, and RhoA phenocopies the effects of miR-31 on metastasis. Cancer Res. 2010;70:5147-5154.